Gwen M C Masclee1, Preciosa M Coloma2, Ernst J Kuipers3, Miriam C J M Sturkenboom4. 1. 1] Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands [2] Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. 2. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. 1] Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands [2] Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: Microscopic colitis (MC) is characterized by chronic watery diarrhea. Recently, several drugs were reported to increase the risk of MC. However, studies lacked a clear exposure definition, did not address duration relationships, and did not take important biases into account. We estimated the risk of MC during drug use. METHODS: This is a population-based nested case-control study using a Dutch primary care database (1999-2013). Incident MC cases (aged ≥18 years) were matched to community-based and colonoscopy-negative controls on age, sex, and primary care practice. Drug use was assessed within 1 and 2 years before the index date. Adjusted odds ratios (OR) were calculated by conditional logistic regression. RESULTS: From the source population of 1,458,410 subjects, 218 cases were matched to 15,045 community controls and 475 colonoscopy-negative controls. Current use (≤3 months) of proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors, low-dose aspirin, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers significantly increased the risk of MC compared with never use in community controls. Adjusted ORs ranged from 2.5 (95% confidence interval (CI): 1.5-4.2) for ACE inhibitors to 7.3 (95% CI: 4.5-12.1) for PPIs in the year prior to the index date. After accounting for diagnostic delay, only use of NSAIDs, PPIs, low-dose aspirin, and ACE inhibitors increased the risk of MC. Compared with colonoscopy controls, only use of PPIs (OR-adjusted 10.6; 1.8-64.2) and NSAIDs (OR-adjusted 5.6; 1.2-27.0) increased the risk of MC. CONCLUSIONS: NSAIDs and PPIs are associated with an increased risk of MC. The association of MC with use of the other drugs is probably explained by worsening of diarrhea/symptoms rather than increasing the risk of MC itself.
OBJECTIVES: Microscopic colitis (MC) is characterized by chronic watery diarrhea. Recently, several drugs were reported to increase the risk of MC. However, studies lacked a clear exposure definition, did not address duration relationships, and did not take important biases into account. We estimated the risk of MC during drug use. METHODS: This is a population-based nested case-control study using a Dutch primary care database (1999-2013). Incident MC cases (aged ≥18 years) were matched to community-based and colonoscopy-negative controls on age, sex, and primary care practice. Drug use was assessed within 1 and 2 years before the index date. Adjusted odds ratios (OR) were calculated by conditional logistic regression. RESULTS: From the source population of 1,458,410 subjects, 218 cases were matched to 15,045 community controls and 475 colonoscopy-negative controls. Current use (≤3 months) of proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors, low-dose aspirin, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers significantly increased the risk of MC compared with never use in community controls. Adjusted ORs ranged from 2.5 (95% confidence interval (CI): 1.5-4.2) for ACE inhibitors to 7.3 (95% CI: 4.5-12.1) for PPIs in the year prior to the index date. After accounting for diagnostic delay, only use of NSAIDs, PPIs, low-dose aspirin, and ACE inhibitors increased the risk of MC. Compared with colonoscopy controls, only use of PPIs (OR-adjusted 10.6; 1.8-64.2) and NSAIDs (OR-adjusted 5.6; 1.2-27.0) increased the risk of MC. CONCLUSIONS: NSAIDs and PPIs are associated with an increased risk of MC. The association of MC with use of the other drugs is probably explained by worsening of diarrhea/symptoms rather than increasing the risk of MC itself.
Authors: D Keszthelyi; S V Jansen; G A Schouten; S de Kort; B Scholtes; L G J B Engels; A A M Masclee Journal: Aliment Pharmacol Ther Date: 2010-09-13 Impact factor: 8.171
Authors: Ole K Bonderup; Morten Fenger-Grøn; Tatjana Wigh; Lars Pedersen; Gunnar L Nielsen Journal: Inflamm Bowel Dis Date: 2014-10 Impact factor: 5.325
Authors: Gwen M C Masclee; Vera E Valkhoff; Preciosa M Coloma; Maria de Ridder; Silvana Romio; Martijn J Schuemie; Ron Herings; Rosa Gini; Giampiero Mazzaglia; Gino Picelli; Lorenza Scotti; Lars Pedersen; Ernst J Kuipers; Johan van der Lei; Miriam C J M Sturkenboom Journal: Gastroenterology Date: 2014-06-14 Impact factor: 22.682
Authors: J M Mullin; M C Valenzano; M Whitby; D Lurie; J D Schmidt; V Jain; O Tully; K Kearney; D Lazowick; G Mercogliano; J J Thornton Journal: Aliment Pharmacol Ther Date: 2008-08-04 Impact factor: 8.171
Authors: Gilles Macaigne; Pierre Lahmek; Christophe Locher; Bruno Lesgourgues; Laurent Costes; Max Pierre Nicolas; Anne Courillon-Mallet; Jean-Michel Ghilain; Guy Bellaïche; Stéphanie de Montigny-Lehnardt; Georges Barjonet; René-Louis Vitte; Roger Faroux; Benedicte Lambare; Antoine Fleury; Alexandre Pariente; Stéphane Nahon Journal: Am J Gastroenterol Date: 2014-07-08 Impact factor: 10.864
Authors: Kristin E Burke; Ashwin N Ananthakrishnan; Paul Lochhead; Po-Hong Liu; Ola Olen; Jonas F Ludvigsson; James M Richter; Shelley S Tworoger; Andrew T Chan; Hamed Khalili Journal: Gastroenterology Date: 2018-08-23 Impact factor: 22.682